WASHINGTON - Indian Prime Minister Narendra Modi arrived in the United States for his first meeting on Monday with US President Donald Trump, seeking to build on growing ties and move beyond disagreements over climate change. Relations between the two nations warmed under Trump's predecessor Barack Obama as India sought greater foreign investment and trade ties with Western nations. Modi vowed to work closely with the Trump administration, but obstacles soon emerged on issues such as trade and visas for Indians wanting to work in the US. Then Trump accused India of seeking to profit from the Paris climate accord as he announced he was pulling out of the deal this month - drawing sharp denials from New Delhi. Officials were eager to downplay expectations of the visit, describing it as no frills - in contrast to Modi's first US visit in 2014, when he basked in a rock star welcome at the Madison Square Garden arena in New York and addressed the United Nations. Natural affinity If there's one thing we want (from the visit), it's chemistry, said one senior Indian official. If the chemistry is good then frankly everything else gets sorted. Some commentators have argued that Modi and Trump should have a natural affinity as political outsiders who have risen to power in part by castigating the traditional ruling elite on a nationalist platform. One US official said the two leaders had a lot in common. We are really seeking to roll out the red carpet, said the official, speaking on condition of anonymity. Initial signs were positive, with the leaders exchanging warm words on Twitter. Important strategic issues to discuss with a true friend! Trump wrote late on Saturday. Thank you @POTUS for the warm personal welcome. Greatly look forward to my meeting and discussions with you @realDonaldTrump, Modi tweeted in response. Modi on Sunday was to meet with top US business leaders - including the heads of Apple, Microsoft and Google - ahead of his meeting the following day with Trump. Trump's protectionist instincts, however, are at odds with India's efforts to boost exports and encourage Western manufacturers to Make In India - a flagship Modi scheme. The Indian leader castigated rising parochial and protectionist attitudes in a speech delivered shortly after Trump took office. A proposed overhaul of H-1B visas - used by thousands of Indian software engineers to work in the US - has also caused concern in New Delhi. Agence France-presse (China Daily 06/26/2017 page12) silicone wristbandsaa wristbandsfidget spinner braceletcustom made rubber braceletswide rubber bands
An employee stacks Johnson& Johnson Neosporin brand boxes on the production line at the J&J consumer healthcare products plant in Lititz, Pennsylvania, the United States. [Photo/Agencies] New drugs developed by pharmaceutical companies from the United States have played an important role in improving healthcare for Chinese, according to China Association of Enterprises with Foreign Investment. International pharmaceutical companies, including those from the US, have kept investing in research and development of new drugs in China, which has also contributed to improved innovation and research capabilities for domestic pharmaceutical companies, said Zuo Yuzeng, chief for communications at the association's R& D-based Pharmaceutical Association Committee. The committee is comprised of 40 international companies with pharmaceutical research and development capabilities, including 12 from the US, such as MSD and Xian Janssen, he said. The companies have brought many patent drugs to Chinese patients. Many were not available in China before, and have contributed to helping patients relieve pain and prolong life, the committee said. A recent new drug that was introduced to China was Sirturo, developed by Xian Janssen Pharmaceutical, a subsidiary of US company Johnson& Johnson. The drug, the first new medication for tuberculosis worldwide for the past 45 years, has been administered in China since Feb 24, and initial results showed it is effective for patients with multidrug-resistant TB, according to Wang Bin, deputy head of disease control and prevention for the National Health Commission. Asgar Rangoonwala, president of Xian Janssen, said the drug is now being used at 16 hospitals nationwide in a trial program. In April, China Drug Administration approved a nine-way HPV vaccine, which works against up to nine types of HPV and was developed by US company MSD. A similar vaccine, which was also developed by the company and works against four types of HPV, was approved by the administration in May last year. Previously, no vaccines were available on the Chinese mainland to effectively prevent cervical cancer, the second most common cancer among Chinese women aged 15 to 44 after breast cancer, except a two-way HPV vaccine, driving many women to Hong Kong to receive such vaccines. International pharmaceutical companies have also contributed to improved capacities in innovation and research of domestic companies through increasing research and development in China, partnering with domestic research institutes and providing training, according to R & D-based Pharmaceutical Association Committee. Some domestic international companies in recent years have been developing fast and they are catching up, said Zuo from the committee.
